CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Bicara Therapeutics Inc.
Sign in to watch- Ticker
- BCAX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-468-4219
- Business address
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $400,716
- in 1 filing, $401K under 10b5-1 plans
Net −$400,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-19 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −6,905 | $18.78 | $130K | 339,392 |
| 2026-03-19 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,905 | 177,703 | ||
| 2026-03-18 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +6,499 | $3.79 | $25K | 345,891 |
| 2026-03-18 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −6,499 | $18.84 | $122K | 339,392 |
| 2026-03-18 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,499 | 184,608 | ||
| 2026-03-16 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 | +8,000 | $3.79 | $30K | 213,141 |
| 2026-03-16 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −8,000 | $19.66 | $157K | 205,141 |
| 2026-03-16 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −4,500 | $19.66 | $88K | 200,641 |
| 2026-03-16 | Cohlhepp Ryan President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,000 | 117,334 | ||
| 2026-03-09 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +36,766 | $3.79 | $139K | 376,158 |
| 2026-03-09 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −36,766 | $19.17 | $705K | 339,392 |
| 2026-03-09 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −36,766 | 191,107 | ||
| 2026-03-06 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +3,817 | $3.79 | $14K | 343,209 |
| 2026-03-06 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −3,817 | $18.75 | $72K | 339,392 |
| 2026-03-06 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,817 | 227,873 | ||
| 2026-03-05 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +1,786 | $3.79 | $7K | 341,178 |
| 2026-03-05 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −1,786 | $18.74 | $33K | 339,392 |
| 2026-03-05 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,786 | 231,690 | ||
| 2026-03-04 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +2,631 | $3.79 | $10K | 342,023 |
| 2026-03-04 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −2,631 | $18.73 | $49K | 339,392 |
Page 5 of 14 · 276 trades